Compare Bio-Rad Laboratories, Inc. Class A Common Stock (BIO) vs Global E Online Ltd (GLBE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Bio-Rad Laboratories, Inc. Class A Common Stock vs Global E Online Ltd — how do they compare? Bio-Rad Laboratories, Inc. Class A Common Stock trades at $298.3 (market cap $8.04B), while Global E Online Ltd trades at $38.51 (market cap $6.51B). The key difference: Bio-Rad Laboratories, Inc. Class A Common Stock is the larger of the two by market cap, and Global E Online Ltd is trading nearer its 52-week high, Bio-Rad Laboratories, Inc. Class A Common Stock nearer its low. Which is the better fit depends on your goals.
| BIO | GLBE | |
|---|---|---|
Market Cap | $8.04B | $6.51B |
Sector | Health | Technology |
52-Week High | $339.75 | $41.59 |
52-Week Low | $241.71 | $27.54 |
Enterprise Value | $7.85B | $5.98B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BIO trades at $297.58, up 0.5% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $305. The stock shows strong profitability with a 51.87% gross margin and positive net income of $760M in 2025, though recent quarters have seen EPS misses. Cash flow from operations remains robust at $532M, supporting financial stability.
Outlook is cautiously optimistic with analyst support, but risks include earnings volatility and high P/E valuation. The company's return to profitability and solid balance sheet provide a foundation for growth, though investors should monitor execution against future earnings expectations and competitive pressures in the biotech sector.
GLBE trades at $38.68, up 0.52% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported strong Q1 2026 results with revenue growth of 33% year-over-year and raised full-year guidance, achieving a 'Rule of 50' metric. Recent acquisition of Passport enhances logistics capabilities, supporting future growth. Valuation remains elevated with a P/E of 57.84 and P/S of 6.7, reflecting high growth expectations.
Outlook is positive driven by robust merchant demand and cross-border expansion, though risks include execution of acquisitions and competitive pressures. Analysts are unanimously bullish with a $38 consensus target, near the current price. Stock investors should monitor earnings consistency and integration success for sustained upside.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Bio-Rad Laboratories, Inc. Class A Common Stock
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and markets products and solutions for the clinical diagnostics and life sciences markets. In diagnostics (53% of sales), Bio-Rad manufactures, sells, and supports test systems and specialized quality controls for clinical laboratories. In life sciences (47% of sales), the firm develops and manufactures a range of instruments and reagents used in research, biopharmaceutical production, and food testing. The company is geographically diverse, with major markets in the Americas (42% of 2021 sales), Europe and Africa (33%), and Asia-Pacific (25%). Bio-Rad owns 37% of Sartorius AG, a laboratory and biopharmaceutical supplier.
Read more on BIO →About Global E Online Ltd
Global-e provides a platform for cross-border e-commerce, helping retailers increase international sales by localizing the shopping experience for consumers in over 200 destinations worldwide.
Read more on GLBE →
